Soleno Therapeutics Announces Appointment of Industry Veteran Matthew Pauls, J.D., M.B.A. to Board of Directors
16 Agosto 2023 - 9:00AM
Soleno Therapeutics, Inc. (Soleno) (NASDAQ: SLNO), a clinical-stage
biopharmaceutical company developing novel therapeutics for the
treatment of rare diseases, today announced the appointment of
Matthew Pauls, J.D., M.B.A, to its Board of Directors, effective
August 15, 2023. Mr. Pauls is an accomplished industry veteran with
extensive executive leadership, strategic and commercial
experience.
“Matt is a highly accomplished biopharmaceutical executive, and
we are pleased to welcome him to the Board,” said Ernest Mario,
Ph.D., Chairman of the Board of Directors of Soleno. “His
impressive track record, including in rare diseases, will be
invaluable as we advance DCCR, our late-stage Prader-Willi syndrome
product candidate, toward planned regulatory filing and potential
approval. We look forward to leveraging Matt’s deep strategic,
operational and commercial expertise to maximize value for both
patients and shareholders.”
Mr. Pauls said, “I am excited to be joining the Soleno Board at
this important time for the company. I believe that DCCR has the
potential to transform the lives of patients with PWS, and I look
forward to working collaboratively with the Board and the
management team to best position the company for success as we
approach potential approval and commercialization.”
Mr. Pauls brings more than three decades of experience in the
biopharmaceutical industry. Since 2020, Mr. Pauls has served as
Chair of the Board of Directors and Chief Executive Officer of
Savara, Inc., a biopharmaceutical company focused on rare
respiratory diseases. He is also a member of the Board of Directors
at Amplo Biotechnology, a private gene therapy company focused on
rare neuromuscular disorders. From 2014 to 2019, Mr. Pauls was
President and Chief Executive Officer and a member of the Board of
Directors of Strongbridge Biopharma plc., a publicly traded
rare-disease focused biopharmaceutical company that he took public
via IPO on the NASDAQ. Prior to 2014, he served as Chief Commercial
Officer of Insmed, Inc., where he led both the global Commercial
and CMC/Technical Operations teams. Prior to Insmed, Mr. Pauls
worked at Shire Pharmaceuticals, most recently as Senior Vice
President, Head of Global Commercial Operations, and earlier in his
career held senior U.S. and global commercial leadership positions
at Bristol-Myers Squibb and Johnson & Johnson. In addition to
his Board positions at Savara and Strongbridge, Mr. Pauls has also
served as Chair of the Board of Directors of Mast Therapeutics and
was a member of the Board of Directors of Zyla Life Sciences. Mr.
Pauls holds B.S. and M.B.A. degrees from Central Michigan
University and a J.D. from Michigan State University College of
Law.
About Soleno Therapeutics, Inc.Soleno is
focused on the development and commercialization of novel
therapeutics for the treatment of rare diseases. The company’s lead
candidate, DCCR extended-release tablets, a once-daily oral tablet
for the treatment of Prader-Willi syndrome (PWS), is currently
being evaluated in a Phase 3 clinical development program. For more
information, please visit www.soleno.life.
Forward-Looking StatementsThis press release
contains forward-looking statements within the meaning of Section
21E of the Securities Exchange Act of 1934, as amended. All
statements other than statements of historical facts contained in
this press release are forward-looking statements, including
statements regarding the receipt of top-line data from the
randomized withdrawal period, and the timing of any regulatory
process or ultimate approvals and determining a path forward for
DCCR for the treatment of PWS. In some cases, you can identify
forward-looking statements by terms such as "may," "will,"
"should," "expect," "plan," "anticipate," "could," "intend,"
"target," "project," "contemplates," "believes," "estimates,"
"predicts," "potential" or "continue" or the negative of these
terms or other similar expressions. These forward-looking
statements speak only as of the date of this press release and are
subject to a number of risks, uncertainties and assumptions,
including the risks and uncertainties associated with market
conditions, as well as risks and uncertainties inherent in Soleno’s
business, including those described in the company's prior press
releases and in the periodic reports it files with the SEC. The
events and circumstances reflected in the company's forward-looking
statements may not be achieved or occur and actual results could
differ materially from those projected in the forward-looking
statements. Except as required by applicable law, the company does
not plan to publicly update or revise any forward-looking
statements contained herein, whether as a result of any new
information, future events, changed circumstances or otherwise.
Corporate Contact:Brian RitchieLifeSci
Advisors, LLC212-915-2578
Soleno Therapeutics (NASDAQ:SLNO)
Gráfico Histórico do Ativo
De Abr 2024 até Mai 2024
Soleno Therapeutics (NASDAQ:SLNO)
Gráfico Histórico do Ativo
De Mai 2023 até Mai 2024